ID: ALA4745005

Max Phase: Preclinical

Molecular Formula: C31H34N2O5S

Molecular Weight: 546.69

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC(C)(C)CC(=O)N1CC[C@@]2(C(=O)Nc3ccccc32)[C@@H]1c1cccc(-c2ccc(CO)c(S(C)(=O)=O)c2)c1

Standard InChI:  InChI=1S/C31H34N2O5S/c1-30(2,3)18-27(35)33-15-14-31(24-10-5-6-11-25(24)32-29(31)36)28(33)22-9-7-8-20(16-22)21-12-13-23(19-34)26(17-21)39(4,37)38/h5-13,16-17,28,34H,14-15,18-19H2,1-4H3,(H,32,36)/t28-,31-/m0/s1

Standard InChI Key:  CUNZKYVACXRKTP-IZEXYCQBSA-N

Associated Targets(Human)

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha 132 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta 97 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

LXR-beta 3841 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

U-87 MG 3946 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 546.69Molecular Weight (Monoisotopic): 546.2188AlogP: 4.85#Rotatable Bonds: 5
Polar Surface Area: 103.78Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.13CX Basic pKa: CX LogP: 3.59CX LogD: 3.59
Aromatic Rings: 3Heavy Atoms: 39QED Weighted: 0.48Np Likeness Score: -0.06

References

1. Chen H,Chen Z,Zhang Z,Li Y,Zhang S,Jiang F,Wei J,Ding P,Zhou H,Gu Q,Xu J.  (2020)  Discovery of new LXRβ agonists as glioblastoma inhibitors.,  194  [PMID:32248003] [10.1016/j.ejmech.2020.112240]

Source